HOPA's Practice Outcomes and Professional Benchmarking Committee (POPBC) conducted a multi-organization, voluntary survey of HOPA members between March of 2021 and January of 2022. The purpose was to better understand the landscape of oncology pharmacy at healthcare organizations throughout the United States.

The research examined: institutional description, job function, staffing, and training/certification. Data were evaluated using descriptive statistics. The analysis found that as the number of patients with cancer rises, the oncology workforce must grow. The current oncology pharmacy practice landscape can serve as a foundation for future research, metrics, and benchmarks.

This research was published in the Journal of Oncology Pharmacy Practice.


Authors: Shawn P Griffin, Jessie R Signorelli, Aubrey Lasko, Benjamin J Andrick, David Doan, Shannon Hough, Grazyna Riebandt, and Stephen Harnicar

Early-Stage Non-small Cell Lung Cancer

Late-Breaking HOPA News:Adjuvant Alectinib in Early-Stage Non-small Cell Lung Cancer (NSCLC)

In April 2024, the FDA approved alectinib (Alecensa®) in patients with early-stage ALK-positive non-small cell lung cancer (NSCLC) based on the ALINA trial.

Pharmacist’s Application to Practice: Tislelizumab-jsgr

Kristine Pisikian, PharmD, PGY-1 Pharmacist Resident and Caroline Quinn, PharmD, BCOP, Specialty Clinical Program Director at Prime Therapeutics write about Tislelizumab-jsgr.

medical illustration of inflamation from osteoporosis

Late-Breaking HOPA News: Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease on Denosumab Therapy

Originally approved for the treatment of osteoporosis in postmenopausal women at high risk for fractures, denosumab is now frequently used in the management of hypercalcemia of malignancy and to decrease skeletal-related events for certain cancer patients